Today: 7 February 2026
Subscribe
Browse Category

Biotech News News 10 November 2025 - 24 November 2025

CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy

CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy

Monday, November 24, 2025 Clearside Biomedical’s CLSD stock is in freefall today after the eye‑disease biotech announced a voluntary Chapter 11 bankruptcy filing and plans to pursue a court‑supervised sale of its business and assets. By late afternoon on Monday, CLSD was trading around $0.88, down roughly 68% on the day, according to intraday pricing data from MarketBeat. MarketBeat+1 Earlier in the session, multiple outlets reported the shares sliding to roughly $0.85–$0.86 following the news, a collapse from Friday’s close at $2.69 and a new 52‑week low. TradingView+2Nasdaq+2 Key Takeaways for CLSD Stock Today CLSD Stock Price Today: A Collapse
24 November 2025
··
OSR Holdings (OSRH) Jumps Over 15% Today on Vaximm Deal Momentum: Stock Price, Nasdaq Risk and What Comes Next

OSR Holdings (OSRH) Jumps Over 15% Today on Vaximm Deal Momentum: Stock Price, Nasdaq Risk and What Comes Next

OSR Holdings, Inc. (NASDAQ: OSRH) is back on traders’ screens today, November 24, 2025, with the micro-cap healthcare stock extending last week’s rally sparked by its cancer-immunotherapy subsidiary Vaximm AG. As of early afternoon U.S. trading on Monday, OSRH is changing hands around $0.65, up roughly 15–16% versus Friday’s close near $0.56.Finviz The move builds on sharp gains posted after Vaximm announced a lucrative non‑binding term sheet with BCM Europe AG for its lead oral cancer vaccine platform, VXM01.PR Newswire+1 This article is for information and education only and does not constitute financial or investment advice. OSRH stock price today:
24 November 2025
··
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

All figures current as of the U.S. market close on Friday, November 21, 2025. NVAX will next trade when markets reopen on Monday, November 24, 2025. Quick snapshot for NVAX heading into November 24, 2025 Novavax stock price today: where NVAX stands Going into Monday, November 24, 2025, Novavax shares are coming off a choppy stretch. In other words, NVAX is trading like a classic high‑beta biotech: small‑cap, volatile, and highly sensitive to news about regulation, partnerships and activist investors. Latest Novavax news investors need to know 1. Q3 2025 earnings: revenue beat, but losses widen and profitability delayed On
24 November 2025
··
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out a new three‑year strategy, taking on $1.5 billion in debt, cutting pipeline projects and doubling down on its mRNA platform in respiratory disease and cancer. Reuters+3Financial Times+3Barron’s+3 Here’s a detailed look at Moderna stock today, what changed this week, and how the latest headlines might shape the risk–reward for investors. Moderna stock price snapshot for November 23, 2025 U.S. markets
23 November 2025
····
Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2 At the time of writing, Nuvation Bio shares trade around $7.15, up roughly 49% today, with an intraday high of $7.21 and heavy trading volume, extending a massive multi‑day rally. Quiver Quantitative Key Takeaways for November 20, 2025 NUVB Stock: From Under‑the‑Radar Biotech to Market Standout The
20 November 2025
·
Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened and what comes next. By Staff Reporter — November 14, 2025 NEW YORK — Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) were under heavy pressure on Friday after the European Medicines Agency’s human medicines committee signaled it is leaning against approving the company’s experimental Alzheimer’s pill blarcamesine for early Alzheimer’s disease. Investing News Network (INN)+1 The Committee for Medicinal
14 November 2025
··
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (NASDAQ: MRSN) is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire Below is a complete roundup of today’s major developments around Mersana Therapeutics (MRSN) — structured and optimized for readers who find this via Google News or Discover. Today’s Mersana (MRSN) Headlines at a Glance – 13
13 November 2025
····
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about November 12, 2025,” pending customary conditions, including consummation of the Decoy transaction. PR Newswire Key takeaways What happened today (Nov. 12, 2025) Salarius confirmed the pricing of its offering for gross proceeds of ~$7 million before fees. The package includes: The company notes the registration statement on Form S‑1 (File No. 333‑284368) became effective on Nov. 10, 2025, and the
12 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed today and how it fits into Merck’s 2025 storyline. Today’s highlights at a glance Market move: why MRK is in focus today Merck shares traded higher on Wednesday after back‑to‑back catalysts in cardiometabolic and oncology. The stock’s strength follows AHA 2025 presentations showing that enlicitide—a once‑daily oral PCSK9 inhibitor—cut LDL‑C by 55.8% at 24 weeks vs. placebo in broad hypercholesterolemia
12 November 2025
··
Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

What moved ASBP today (Nov. 11) Trading in Aspire Biopharma swung sharply. A pre‑market “health‑care movers” screen showed ASBP briefly up more than 30%, before regular‑session selling pulled shares lower on very heavy volume. Mid‑session, ASBP was down roughly 20–25% versus Monday’s close, with an exceptionally wide intraday range—characteristic of micro‑cap names facing near‑term listing and financing milestones. Benzinga While price action is noisy, there were no fresh corporate announcements today. The latest company communication remains last week’s trade‑show recap from CPHI Frankfurt, where Aspire says it held 16 formal meetings and multiple informal conversations with global pharmas regarding potential
11 November 2025
··
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 Today’s headlines at a glance Why the MeiraGTx move matters The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind (regulators are evaluating expedited
10 November 2025
···
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Key takeaways Why this matters for patients and investors Damora’s approach is aimed squarely at mutant calreticulin (mutCALR)—a well‑validated genetic driver in segments of essential thrombocythemia (ET) and myelofibrosis (MF). Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond
10 November 2025
·····
1 … 8 9 10 11 12

Stock Market Today

Go toTop